GPN Vaccines has raised $10.0M as the clinical-stage company works on vaccines against some of the world's most important bacterial pathogens. The Australian firm is developing products designed to provide robust protection against these threats.

Get the full GPN Vaccines company profile
Access contacts, investors, buying signals & more
GPN Vaccines has raised $10.0M as the clinical-stage company works on vaccines against some of the world's most important bacterial pathogens. The Australian firm is developing products designed to provide robust protection against these threats.
GPN Vaccines Raises $10 Million To Advance Gamma-PN Pneumococcal Vaccine Toward Phase 2 Trials GPN Vaccines Raises $10 Million To Advance Gamma-PN Pneumococcal Vaccine Toward Phase 2 Trials GPN Vaccines, a clinical-stage biotechnology company developing broadly protective bacterial vaccines, has closed a fully subscribed $10 million private placement with participation from new and existing investors.
The financing will support preparations to advance its lead investigational vaccine, Gamma-PN, into Phase 2 clinical development. The proceeds will fund several development activities, including current Good Manufacturing Practice (cGMP) batch manufacturing, expansion of the company鈥檚 opsonophagocytic activity (OPA) testing laboratory, and preparation of an Investigational New Drug application for

Vudoo
Vudoo is a commerce media platform that embeds checkout directly into any media format, including ads, video, CTV, social, and editorial content. It enables instant transactions within the content consumers are already engaging with, turning attention into measurable commerce outcomes. The platform serves advertisers, ad tech companies, agencies, and media owners, and is expanding into agentic commerce for AI-driven shopping experiences.
$15.4M Series b
1 day ago

Reckless Brewing Company
Reckless Brewing was born from a simple belief: the Australian beer market didn鈥檛 need more beer - it needed better thinking. As craft became increasingly niche and intimidating, and mainstream beer chased scale at the expense of flavour, we saw a gap. Australian-owned beer didn鈥檛 have to choose between quality and approachability. From day one, our rule has been clear: every beer must be exceptional in flavour, genuinely sessionable and easy to come back to. Female-Led. Commercially Driven. Proudly based in Bathurst in the Central West of NSW, Reckless is majority women-founded and women-led in an industry still dominated by male voices. That perspective isn鈥檛 symbolic, it鈥檚 a competitive advantage. Regional Roots. National Momentum. Rather than fighting for attention in crowded capital cities, we built a powerhouse in regional Australia. Our 400+ seat brewery, taproom and restaurant has become one of Bathurst鈥檚 largest hospitality venues and a recognised tourism destination. Two Brands. One Clear Strategy. We鈥檝e deliberately built two complementary brands to maximise reach. Reckless Brewing Co. is our flagship craft label, focused on bold styles, seasonal releases and quality-led experimentation. BX is our easy-drinking range - designed to look and drink like a macro beer, but made better. Award-Winning. Innovation-Focused. Our commitment to excellence is proven. Since winning two gold medals from three entries in our first awards in 2021, Reckless has secured 138 medals and eight Champion trophies, spanning styles from XPA to Baltic Porter. Built Differently. Built to Scale. Reckless Brewing is one of Australia鈥檚 fastest-growing independent breweries and the largest female-led brewery in Australia. Operationally disciplined, financially controlled and built to scale, we are only just getting started. Reckless Brewing stands out - because we built it differently.
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 | ![]() NeuroEM Therapeutics United States | Unknown |
Companies that recently closed a Unknown round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Vesalius Longevity Labs Inc. | Unknown | $6.5M | today |
| 2 | ![]() YouFit Gyms | Unknown | $10.0M | today |
$358.1K Crowdfunding
1 day ago
| $7.2B |
| 2y ago |
| 3 | ![]() GRAIL United States | Unknown | $7.1B | 2y ago |
| 4 | ![]() Illumina United States | Unknown | $7.1B | 2y ago |
| 5 | ![]() RemeGen Biosciences United States | Grant | $5.6B | 10mo ago |
| 3 |
![]() ancep |
| Unknown |
| $8.5M |
| today |
| 4 | ![]() Efferon O脺 | Unknown | $4.8M | today |
| 5 | ![]() OneQlue | Unknown | $1.3M | today |
Contacts, investors, buying intent signals & tech stack.
Trusted by 200+ sales teams
See who invested in GPN Vaccines and reach their contacts directly.
Start free trial
Stemora, Inc.
Recently received

Thryv Therapeutics Inc.
Recently received

BionicM
Recently received